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Abstract
Depressive symptoms are common in older adults after a disabling medical event and interfere with rehabilitation and recovery from the disability. This prospective study examined
the role of genetic polymorphisms implicated in synaptic integrity and stress-associated depression as predictors of depressive symptoms after hip fracture. We recruited healthy comparisons from the community and participants with hip fracture after surgical fixation from
Saint Louis, Missouri hospitals. We examined the valine (Val) to methionine (Met) polymorphism in brain-derived neurotrophic factor (BDNF), serotonin 1A receptor (5HT1a-rs6295)
polymorphism, and the serotonin transporter-linked polymorphic region (5HTTLPR) interaction with the rs25531 A to G single nucleotide polymorphism (5HTTLPR-rs25531) as predictors of depressive symptoms. We also examined whether depressive symptoms mediate
the influence of BDNF genotype on functional recovery. Among 429 participants with hip
fracture, BDNF Met/Met carriers developed significantly more depressive symptoms than
Val/Val carriers during a four-week period after the fracture (p = .012). BDNF genotype also
predicted functional recovery over the ensuing year, mediated by its effects on depressive
symptoms (CI: 0.07-3.37). Unlike prior studies of stressful life events, the S0 5HTTLPRrs25531 variant did not predict higher levels of depressive symptoms; instead, we report an
exploratory finding of an epistatic effect between BDNF and 5HTTLPR-rs25531 whereby
the compounded effects of two LA alleles and BDNF Met/Met genotype elevate risk of depressive symptoms after hip fracture (p = .006). No differences between 5HT1a genotypes
were found. Our findings suggest plasticity-related genetic factors contribute to the neural
mechanisms of mental and functional well-being after a disabling medical stressor.
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Introduction
Disabling medical events, such as hip fracture, often trigger depressive symptoms. In fact, most
of the total burden of depressive symptoms in our aging population occurs in the context of
disabling medical events [1–3]. Hip fracture is a common [4] and severe life stressor [5,6]: it
causes pain [7], fear [8], requires hospitalization and surgery [4,6], lengthy and intensive rehabilitation [9], and leads to increased risk of institutionalization and mortality [10–12]. Depressive symptoms after hip fracture have a pernicious effect on the recovery process: they are
associated with higher discharge rates to and increased length of stay in nursing homes [13–
15], poorer occupational and physical therapy participation, and poorer functional recovery
[16,17]. Hip fracture patients with more depressive symptoms are less likely to return to prefracture levels in several areas of physical functioning (such as walking independently) as compared to patients with less depressive symptoms [16,18,19]. Currently, the ability to predict
which persons are at-risk of depressive symptoms after a medical disability is surprisingly low.
Identification of genetic risk factors has the potential to alert caregivers to monitor patients vulnerable for high depressive symptoms. Early-intervention and optimal management of depressive symptoms could then essentially mitigate their impact on functional recovery, thereby
improving quality of life and functional independence in late-life.
The extent to which molecular processes contribute to the neurobiology of depressive symptoms and subsequent functional recovery after a medical stressor is not well understood. Past
research indicates genes associated with synaptic integrity or those vulnerable to stressful
events may influence depressive symptoms [20–22]. In this study, we investigate genetic variants previously associated with depressive symptoms by examining their impact on both depressive symptoms and functional recovery in older adults who have experienced a
medical stressor.

BDNF Val66Met polymorphism
Brain-derived neurotrophic factor (BDNF) is of the neurotrophin family [23] and has beneficial
effects on health, particularly for promoting synaptic plasticity [20,24,25]. However, a valine
(Val) to methionine (Met) substitution at nucleotide 66 (Val66Met; refSNP: rs6265) in the
BDNF gene influences risk of depression in older adults [26–29]. In vivo experiments demonstrate the Met allele results in a reduction of activity-dependent BDNF secretion and a loss of
BDNF protein at the synapse due to abnormal trafficking patterns [30,31]. In addition, the Met
substitution is associated with reduced hippocampal activity [32] and atrophy of the hippocampus in humans [22,33,34], a structure important for mood regulation. The reduction in
hippocampal volume likely reflects a decrease in BDNF protein at the synapse and, consequently, a decrease in synapse formation [30,35,36].

Serotonin-related polymorphisms
In this study, we also assessed putative functional polymorphisms in serotonin (5HT), a hallmark neurotransmitter involved in depression. The gene SLC6A4 encodes for the serotonin
transporter (5HTT) and this transporter’s efficiency is altered by both a genetic variation of the
serotonin transporter gene-linked polymorphic region (5HTTLPR) and a functional A to G
single-nucleotide polymorphism (SNP; refSNP: rs25531) [37,38]. 5HTTLPR is a 44-bp repeat
insertion (long) or deletion (short) in the promoter region resulting in different levels of serotonin transporter expression [39–41]. In depression research, the short (S) allele has been characterized as the susceptible allele due to its reduced ability to remove 5HT from the synaptic cleft
compared to the long (L) allele [42,43]. Additional research has indicated the S and L alleles interact with the alleles of rs25531, such that the combination of the 5HTTLPR L allele and
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rs25531 G allele are equivalent to the S allele alone [38]. Although 5HTTLPR has been extensively studied in younger adults after stressful life events, few studies have examined it in latelife after a disabling medical event as the stressor. Older patients with myocardial infarction
and at least one S allele had higher depressive scores than persons with two L alleles [40]. Similar results were found in older patients with a history of coronary disease [44], following a
stroke [45], and in a small pilot study after hip fracture [46].
The HTR1A gene encodes the serotonin 1A receptor (5HT1a; refSNP: rs6295). 5HT1a hinders the release of serotonin and the G allele of C(-1019)G polymorphism is associated with increased depressive symptoms [47–50].

Hypotheses
Here we examined functional polymorphisms from BDNF and serotonin-related genes as predictors of depressive symptoms after hip fracture. We hypothesized BDNF Met/Met genotype,
5HTTLPR-rs25531 S0 allele, and the G allele of the 5HT1a polymorphism would be associated
with more depressive symptoms, and if so, they would also predict poorer functional recovery
as a result of depressive symptoms. Lastly, we explored the interaction of BDNF and
5HTTLPR-rs25531 on depressive symptoms.

Methods and Materials
Setting and sample
We recruited participants with hip fracture from admissions to eight local hospitals in Saint
Louis, Missouri from 2008–2012 and healthy comparisons from the community via selfreferrals, presentations, advertisements, and the university’s research registry. Washington
University's Human Research Protection Office, Washington University School of Medicine
Institutional Review Board, and the review boards at the applicable participating research site
(The Christian Hospital Research Committee for Christian Hospital, DePaul Institutional Review Board for DePaul Health Center, Missouri Baptist Medical Center Institutional Review
Board for Missouri Baptist Medical Center, Saint Anthony’s Medical Center Institutional Review Board for Saint Anthony's Medical Center, SSM Saint Louis Institutional Review Board
for SSM Saint Clare Health Center, Saint Louis University Institutional Review Board for Saint
Louis University Medical Center Campus and Saint Mary’s Health Center, and Washington
University School of Medicine Institutional Review Board for Barnes-Jewish Hospital) approved this study and approved the informed written consent document that was signed by all
participants. Eligibility for participants with hip fracture included being age 60 or older, primary diagnosis of hip fracture to be surgically repaired, and absence of delirium or dementia. Participants with hip fracture were excluded if they were unable to provide written informed
consent after complete description of the study, were unable to cooperate with the protocol,
had a current diagnosis of major depression, had metastatic cancer, were significantly impaired
by language, visual or hearing barriers, lived more than one hour away, were taking interferon
medications, or had an inoperable fracture. Exclusion criteria for healthy comparisons were
the same but also included persons who had a hip fracture in the past year, a major health
issue, or had been hospitalized in the last six months.
The study was 52 weeks with evaluation time points at baseline (typically two days after surgery), week 1, 2, 4, 8, 12, 26, and 52. We conducted baseline, weeks 4 and 52 in person, and
weeks 1, 2, 8, 12, and 26 by phone.
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Measures
Trained raters measured depressive symptoms with the Montgomery-Asberg Depression Rating Scale (MADRS) [51] at every time point. At baseline, MADRS scores are retrospective: participants described themselves for the week prior to hip fracture or entry to study (for healthy
comparisons). Higher scores indicate more depressive symptoms. Major and Minor Depressive
Disorder were assessed with the Structured Clinical Interview for Diagnostic and Statistical
Manual of Medical Disorders-IV (SCID) [52] at baseline and any subsequent time point if
MADRS > = 10 or if the depressed mood or anhedonia item was > = 2. Participants diagnosed
with Major Depressive Disorder at baseline (reflecting current depression prior to hip fracture)
were excluded. Test-retest reliability for MADRS was ICC = .84 (CI = 0.51–0.95), SCID past
major depression κ = .52, and minor depression κ = .35.
Functional recovery was measured with the Functional Recovery Score (FRS) from the Hospital for Joint Diseases Geriatric Hip Fracture Research Group [53]. The FRS assesses Basic
Activities of Daily Living, Instrumental Activities of Daily Living, and Mobility. A total score
(0–100) is calculated from the three areas with higher scores indicating a greater ability to perform activities. Test-retest reliability was ICC = .75 (CI = 0.24–0.92).
Cognitive performance was assessed with the Short-Blessed Test [54] at baseline, week 4
and 52. Scores >10 warranted further evaluation to ensure absence of dementia or delirium.
Participants rated how stressful they have found their hip fracture as a measure of perceived
stress. Ratings included: (1) not at all stressful, (2) somewhat stressful, or (3) very stressful [55].
Test-retest reliability was κ = .75.

Genotyping
DNA was extracted from saliva and blood samples using standard procedures. For genotyping
of the polymorphisms in the serotonin 1A receptor (rs6295), BDNF (rs6265), and 69 single nucleotide polymorphisms (SNPs) for the population stratification analysis, we used Sequenom
technology, following manufacturer’s protocol. For serotonin transporter polymorphisms, we
followed a protocol which genotypes the SLC6A4 promoter haplotype [38]. In short, it is a triplex polymerase chain reaction protocol followed by double restriction endonuclease digestion,
determining the phase-certain 5HTTLPR VNTR and rs25531 genotypes which are combined
as SA, SG, LA, and LG haplotypes. For analyses, a composite of 5HTTLPR-rs25531 was reflected by the number of LA alleles: LA/LA, LA/S0 , and S0 /S0 [38].

Statistical Analysis
T-tests and chi-square were used to examine demographic and genotype differences between
participants with hip fracture and healthy comparisons.
The main outcome, MADRS scores, had a skewed distribution. Thus, we used generalized
estimating equations (GEE) with a Poisson distribution in SAS 9.3 procedure GENMOD (SAS
Institute, Cary, NC) to examine the polymorphisms as predictors of depression symptoms.
GEE is advised for instances where data will be correlated, such as repeated measurements, and
for non-parametric data. GEE accounts for missed visits and dropouts using the all available
pairs method. Within participants with hip fracture, we assessed main effects of each polymorphism for significance in separate models, with the most common homozygote as reference.
We next ran separate GEE models to evaluate if age, gender, antidepressant use, education, or
Short-Blessed Test were significant covariates. We then investigated the interaction between
BDNF and 5HTTLPR-rs25531 to replicate prior findings. Significance level of p<.05 was set
for main effects; however, due to testing for three polymorphisms, a probability value less than
p<.0167 was considered significant.
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We performed Kaplan-Meier Estimates of Survival Function to examine if the polymorphisms predicted Major and Minor Depressive Disorder. Due to low numbers of participants
with hip fracture developing Major Depressive Disorder, we combined the two diagnoses. Additionally, we expanded the timeframe to eight weeks post-fracture to account for extra time
needed for a clinical interview to make a SCID diagnosis after a MADRS score warranted
further evaluation.
Lastly, mediation analysis using MEDIATE [56,57] in IBM SPSS Statistics 21.0 (Armonk,
NY) was performed to examine BDNF effects on functional recovery through depressive symptoms. Using Helmert coding to address the multicategorical BDNF variable [57], estimation of
coefficients for the first contrast compares Val/Val and Val/Met (Val+) relative to Met/Met
while the second contrast compares Val/Val relative to Val/Met carriers. MADRS scores, averaged from weeks 1 through 4 to reflect high points of depressive symptoms post-fracture,
served as the mediator. FRS was calculated as percent of baseline at week 12, 26, and 52. Indirect effects of BDNF on FRS at week 12, 26, and 52 were conducted using stratified bootstrap
sampling based on 10,000 bootstrap samples. Significance of indirect effects was determined
with biased-corrected confidence intervals (90%) not including zero [58]. Mediation analysis
uses listwise deletion for participants missing data on variables included in each model.
We conducted population structure analysis with Structure Software Version 2.3 [59].
Thirty-five SNPs were selected from a panel of 69 SNPs that were in Hardy-Weinberg equilibrium. Structure parameters included the admixture model assuming independent allele frequencies with 10,000 burn-in period and 50,000 of MCMC reps. Project was run K 1–5 for five
iterations. Results were imported into Structure Harvester Web v0.6.93 to detect the ideal number of clusters [60].

Results
Our initial sample included 558 white (93%), 41 black (7%) and 3 Asian adults (<1%). Investigation of population stratification revealed two populations: those that self-identified as black
and as white. Thus, to reduce variance explained by genetic diversity, data is presented for
white participants only in the analyses [61,62]. At baseline (Table 1), participants with hip fracture were more likely to be female, to have less education, poorer functional scores, and worse
Short-Blessed Test scores than healthy comparisons. We found no differences between participants with hip fracture and comparisons for age, MADRS depressive scores, or antidepressant
use. Genotype frequencies from BDNF-rs6265, 5HTTLPR-rs25531, and 5HT1a-rs6295 were in
Hardy-Weinberg equilibrium.
Our time course data shows hip fracture to be depressogenic from week 1 to 4, followed by a
decline in depressive symptoms (Fig. 1). Therefore, to examine the candidate polymorphisms,
we focused on the four-week period post-fracture where an increase in depressive scores
among participants with hip fracture was observed relative to comparisons.

Main genetic effects on depressive symptoms
Observed MADRS scores by BDNF and 5HTTLPR-rs25531 polymorphisms for participants
with hip fracture are in Fig. 2. To examine differences in depression scores between genotypes,
we entered BDNF, 5HTTLPR-rs25531, and C(-1019)G 5HT1a into separate GEE models that
included time to account for repeated MADRS measures (Table 2). BDNF Met/Met carriers
had significantly higher MADRS scores than Val/Val carriers (p = .012). For 5HTTLPRrs25531, both S0 /S0 (p = .032) and LA/S0 (p = .016) carriers had lower MADRS scores compared
to LA/LA carriers. The 5HT1a model was not significant. Inclusion of all races/ethnicities in
GEE models produced similar results (not shown).
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Table 1. Baseline demographic variables and summary of frequencies for BDNF Val66Met, 5HTTLPR-rs25531, and C(-1019)G 5HT1a
(Caucasian only).
Characteristic

Healthy Comparisons
(n = 92)

Participants with Hip
Fracture (n = 466)

Mean

SD

Mean

SD

t

p

Age (years)

78.3

7.1

78.9

8.5

-0.73

.47

Education, yearsa

15.2

2.8

13.04

2.8

6.45

<.001

Short-Blessed Test

1.9

2.5

4.6

3.3

-9.01

<.001

MADRS Depression Score

3.2

3.4

3.2

4.1

-0.19

.85

Functional Recovery Score

98.1

3.8

94.9

9.4

5.31

<.001

N

%

N

%

χ2

p

Female

60

65

352

76

4.23

.04

On Antidepressantsa

15

17

97

21

0.66

.42

0.03

.86

1.35

.51

2.36

.12

BDNF Val66Meta
Val/Val

60

66

290

67

Val/Met

30

33

123

29

Met/Met

1

1

16

4

22

24

110

25

S /LA

47

51

199

46

LA/LA

23

25

125

29

5HTTLPR-rs25531a
S0 /S0
0

5HT1a C(-1019)Ga
CC

27

30

95

22

CG

44

48

229

54

GG

20

22

100

24

Abbreviations: 5HT1a, Serotonin 1A receptor; 5HTTLPR, serotonin transporter gene-linked polymorphic region; BDNF, brain-derived neurotrophic factor;
MADRS, Montgomery-Asberg Depression Rating Scale.
a

Reduced N

doi:10.1371/journal.pone.0120685.t001

Fig 1. Observed Montgomery-Asberg Depression Rating Scale (MADRS) scores over time for participants with hip fracture and healthy
comparisons. The number of participants with hip fracture and healthy comparisons are listed below the figure.
doi:10.1371/journal.pone.0120685.g001
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Fig 2. Observed Montgomery-Asberg Depression Rating Scale (MADRS) scores for participants with hip fracture.
doi:10.1371/journal.pone.0120685.g002

We next examined which covariates were predictive of MADRS scores. Gender, age, education, and Short-Blessed Test scores were not significant. Antidepressant use significantly
predicted MADRS scores (b = 0.24, SE = .08, p = .005). The polymorphisms were therefore reexamined after including time and antidepressant use (S1 Table). Antidepressant use remained
significant in all models, indicating participants on antidepressants had higher MADRS scores.
Like the model without antidepressant use, the same trends were seen for BDNF, 5HTTLPRrs25531, and 5HT1a.

Exploring an interaction between BDNF and 5HTTLPR-rs25531
Table 2 also summarizes the significant interaction between BDNF and 5HTTLPR-rs25531. As
displayed in Fig. 3, Met/Met carriers had significantly higher MADRS scores than Val/Val carriers among participants with two LA alleles, whereas this distinction was not observed among
S0 carriers. The interaction remained significant after including time and antidepressant use
(p = .014; S1 Table).

Genetic results for participants with high-perceived stress
We further analyzed results by including only participants who perceived the hip fracture as
stressful. Five percent of participants who rated the hip fracture as “not at all stressful” had
lower MADRS scores than 68% of participants who rated it “very stressful” (p = .005) and 27%
of participants who rated it “somewhat stressful” (p<.001). Analyses were re-examined by excluding those who reported the event as being “not at all stressful” (S2 Table). As in the aforementioned results, we found the same trends for the main effects of the at-risk polymorphisms
using uncorrected p-values in this high-perceived stressed subsample. The interaction between
BDNF and 5HTTLPR-rs25531 remained significant (p = .011).
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Table 2. Parameter estimates (log) and empirical standard error estimates with time for four GEE models predicting MADRS depressive scores
post-fracture.
Gene Predicting Depressive Scores

SE

Z

1.72

0.05

31.77

<.001

Time BL—Week 4

-0.58

0.07

-8.66

<.001
.012

BDNF Val66Met

Intercept

(n = 429)

5-HTTLPR/rs25531
(n = 434)

Estimate

Met/Met—Val/Val

0.39

0.16

2.50

Val/Met—Val/Val

0.01

0.09

0.16

.869

Intercept

1.88

0.07

26.54

<.001

Time BL—Week 4

-0.58

0.07

-8.72

<.001

S0 /S0 —LA/LA

-0.20

0.09

-2.15

.032

LA/S0 —LA/LA

-0.20

0.09

-2.40

.016

1.65

0.07

22.89

<.001

-0.59

0.07

-8.84

<.001

GG—CC

0.09

0.10

0.93

.353

CG—CC

0.13

0.09

1.49

.136

Intercept

1.78

0.09

20.30

<.001

5HT1a C(-1019)G

Intercept

(n = 424)

Time BL—Week 4

BDNF Val66Met x

p

5HTTLPR-rs25531

Time BL—Week 4

-0.58

0.07

-8.64

<.001

(n = 428)

Met/Met—Val/Val

0.67

0.13

5.08

<.001

Val/Met—Val/Val

0.22

0.13

1.65

.099

S0 /S0 —LA/LA

-0.09

0.12

-0.72

.473

LA/S0 —LA/LA

-0.09

0.10

-0.89

.373

a

-0.85

0.31

-2.76

.006e

b

Estimate 2

-0.21

0.31

-0.68

.494

Estimate 3c

-0.24

0.20

-1.15

.250

Estimate 4d

-0.32

0.20

-1.63

.104

Estimate 1

Abbreviations: 5HT1a, Serotonin 1A receptor; 5HTTLPR, serotonin transporter gene-linked polymorphic region; BDNF, brain-derived neurotrophic factor;
BL, baseline; GEE, generalized estimating equation; MADRS, Montgomery-Asberg Depression Rating Scale.
The estimated intercept (log) for each of the models refers to MADRS depressive scores for carriers of the reference (common homozygote) genotype.
For example, irrespective of BDNF genotype, the intercept for all participants with hip fracture was 1.72 and relative to Val/Val carriers, Met/Met carriers
had 0.39 units higher MADRS scores. The interaction estimates are interpreted as follows:
The difference between Met/Met carriers and Val/Val carriers within LA/LA minus the difference between Met/Met carriers and Val/Val carriers within S0 /S0 .
The difference between Met/Met carriers and Val/Val carriers within LA/LA minus the difference between Met/Met carriers and Val/Val carriers within LA/S0 .

a
b

The difference between Val/Met carriers and Val/Val carriers within LA/LA minus the difference between Val/Met carriers and Val/Val carriers within S0 /S0 .

c

The difference between Val/Met carriers and Val/Val carriers within LA/LA minus the difference between Val/Met carriers and Val/Val carriers within LA/S0 .
Contrast results for GEE analysis of the interaction indicate a signiﬁcant difference between BDNF Met/Met and Val/Val carriers within LA/LA (χ2 = 4.37(1),

d
e

p = .037) and between BDNF Met/Met and Val/Met carriers within LA/LA (χ2 = 3.86(1), p = .050).
doi:10.1371/journal.pone.0120685.t002

Genetic risk for Major and Minor Depressive Disorder
We examined if the polymorphisms predicted incident depression diagnosis during the eight
weeks post-fracture. The log rank tests from Kaplan-Meier survival estimates indicated no significant differences between genotypes for BDNF Val66Met (χ2 = 0.81(2), p = .67), 5HTTLPRrs25531 (χ2 = 0.31(2), p = .86), or 5HT1a (χ2 = 2.36(2), p = .31).

Mediation test of BDNF on FRS through depressive symptoms
The indirect effects from the mediation analysis were significant and indicated BDNF genotype
affects functional recovery as a result of depressive symptoms at weeks 12, 26, and 52

PLOS ONE | DOI:10.1371/journal.pone.0120685 March 17, 2015
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Fig 3. Predicted values for the interaction effect between brain-derived neurotrophic factor (BDNF) and serotonin transporter gene-linked
polymorphic region, 5HTTLPR-rs25531 . Within hip fracture participants with two 5HTTLPR-rs25531 LA alleles (LA/LA), contrast results for the GEE
analysis indicate BDNF Met/Met carriers had significantly higher depressive symptoms than Val/Val carriers (χ2 = 4.37(1), p = .037) and Val/Met carriers
(χ2 = 3.86(1), p = .05). Sample sizes are listed below each graph. Abbreviations: MADRS, Montgomery-Asberg Depression Rating Scale; GEE, Generalized
estimating equations.
doi:10.1371/journal.pone.0120685.g003

(S3 Table). Total, direct, and indirect effects for the Val+:Met/Met contrast at week 12 are provided in Fig. 4 for illustration. The total effect indicated Val+ carriers had significantly better
FRS than Met/Met carriers at week 12. The direct effects indicated Val+ carriers had significantly lower MADRS scores relative to Met/Met carriers and participants with lower MADRS
scores had higher FRS, regardless of BDNF genotype, at all 3 time points. Indirect effects indicated MADRS scores are a significant mediator for the Val+:Met/Met contrast. That is, Val+
carriers scored an average 1.728 units higher on FRS at week 12 relative to Met/Met carriers
due to the effect of BDNF genotype on depressive symptoms. Similar results were seen using
FRS as the outcome at week 26 and 52. Neither total, direct, nor indirect effects for the Val/Val:
Val/Met contrast were significant. There was no evidence that BDNF genotype influenced FRS
independent of its effect on depressive symptoms at week 12, 26, or 52 for either contrast.
a
Independent of MADRS scores, FRS was not influenced by the direct effect of BDNF Val+
relative to Met/Met (p = .09).

Discussion
Depressive symptoms are commonplace after a disabling medical event, can increase risk and
length of stay in nursing homes, and impede functional recovery [13,16,17]. In this study, we
sought to identify responsible genetic mechanisms underlying the neurobiological mental and
functional consequences that arise after a medical stressor.
This longitudinal analysis provided several noteworthy findings. Results indicate hip fracture participants with two BDNF Met alleles have higher depressive symptoms than Val/Val
carriers in the first weeks post-fracture. Analyses also indicated BDNF Met/Met carriers were
more likely to have poorer functional recovery scores for a year after hip fracture as a result of
BDNF genotype on depressive symptoms. We did not find the expected association between
the 5HTTLPR-rs25531 short allele and depressive symptoms; however, we report an interaction between BDNF and 5HTTLPR-rs25531. Although the interaction needs to be further explored in a more suitably sized cohort, our current sample indicated BDNF Met/Met carriers

PLOS ONE | DOI:10.1371/journal.pone.0120685 March 17, 2015

9 / 16

Functional Polymorphisms in Stress-Associated Depression

Fig 4. Mediation model using Hayes’ (2013) multicategorical independent variable method . Mediation
test of the relationship between brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and the
Functional Recovery Score (FRS) at week 12 as a result of the Montgomery-Asberg Depression Rating Scale
(MADRS) depression scores. Results are shown for the BDNF Val+:Met/Met contrast. The Val/Val:Val/Met
contrast was not significant.
doi:10.1371/journal.pone.0120685.g004

have higher depressive symptoms than Val/Met and Val/Val carriers in the presence of
two LA alleles.
Understanding the neurobiological consequences of genes arising after a medical stressor is
not only important for identifying older adults at risk of higher depressive symptoms, but secondarily, as our data (and others’) suggests [63,64], also significant for their functional recovery. BDNF generally plays an important role in synaptic plasticity [20], however, the Met allele
at the Val66Met polymorphism results in abnormal neurotrophin trafficking patterns in neuronal cells. More specifically, the BDNF Val protein is localized more in the axon terminal,
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whereas expression of the BDNF Met protein has most localization in the cell body [30,31]. In
consequence, a loss of BDNF at the axonal terminal among Met/Met carriers may compromise
formation of new synapses [30,31,33,35,36]. Considering previous studies have indicated that
atrophy of the hippocampus [22,33] and reduced hippocampal activity [32] are associated with
the Met allele, BDNF Met/Met carriers may be vulnerable to the development of depressive
symptoms due to inadequate synaptic formation in the hippocampus, a structure important
for mood regulation [26,34,35,65,66].
The serotonergic system has long been a focus of research on the genetic origins of depression. Studies, like Caspi’s [42], investigating 5HTTLPR and depression, have been particularly
arguable in the context of gene-environment effects [67,68]. While several previous studies
have observed the 5HTTLPR short allele is related to depression due to less efficient transcription of serotonin transporters [43], others have found no association of 5HTTLPR and depression [69]. The different conclusions may be due to prior observations having smaller sample
sizes [46], examining a history of life events rather than an acute medical event, having younger
subjects, or not accounting for the influence of rs25531 A>G on 5HTTLPR [70]. Our current
observations suggest the phenomenon may be pathophysiologically different after a medical
stressor, or as Taylor and colleagues [71] findings indicate, neurostructural differences are evident between early and late-onset depression. Among older adults classified as having depression after age 50, results showed those who were homozygous with the L/L genotype had
smaller hippocampal volume than those with early-onset depression. Future efforts should include the concerted genetic mechanisms among serotonin-related polymorphisms as well as
compare genetic differences between persons with progressive medical events (i.e. stroke, heart
disease) to those with injury-related medical events as investigated here.
We also explored a gene-gene interaction due to existing reports linking neurotrophins with
serotonin in depression literature [72,73] and research suggesting compounded effects of certain genes can heighten risk of psychiatric symptoms [74]. In this study, the interaction between BDNF and 5HTTLPR-rs25531 was specific to LA/LA carriers. Particularly, significant
differences in depressive symptoms were found between Met/Met and Val+ carriers among
LA/LA carriers only; the interaction was not significant among S0 carriers. Thus, the short allele
appears to contribute protection against depressive symptoms in persons with the at-risk
BDNF genotype. While an inclusive model explaining the neurotrophin-serotonin association
is unknown, past research indicates a dynamic relationship between the two signaling systems.
The BDNF protein contributes to the survival and plasticity of serotonergic neurons as well as
plays a role in serotonin secretion via BDNF’s TrkB receptors. Additional studies have also
demonstrated stress reduces BDNF and serotonin levels [72,73]. Conceivably, and like most
bodily systems, a homeostatic equilibrium would be achieved between the two signaling systems under normal conditions regardless of one’s BDNF and 5HTTLPR-rs25531 alleles. However, it could be speculated that LA/LA carriers with normal functioning 5HT transcription,
combined with the suboptimal BDNF Met substitution, are more vulnerable during a stressful
situation. That is, a further reduction of BDNF due to stress could impact BDNF’s ability to
contribute to the survival and functioning of serotoninergic neurons, whereas the less functional serotonin system among S0 carriers has learned to adapt with neurotrophins over time
and may be more resistant to stressors. Further studies, specifically ones that reveal how the
neurotrophin-serotonin systems adapt to maintain homeostasis over time and how they interact as a result of a stressful experience at the biological level, are needed.
Similar results have also been found for neuroticism and cortisol levels: BDNF Met carriers
homozygous for 5HTTLPR L allele have increased neuroticism scores [75], and, in children,
BDNF Met carriers with at least one 5HTTLPR L allele have higher cortisol levels [76]. In contrast, studies investigating stressful life events found higher depression among Korean older
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adults [28] and maltreated children [77] with BDNF Met and 5HTTLPR S0 allele. As opposed
to limiting investigations to a single gene, further studies examining net effects of BDNF and serotonin-related polymorphisms may better explain stress-associated depression risk factors
[62]. This is particularly true in consideration of the complexity underlying depression
pathophysiology.
In contrast to the high levels of depressive symptoms in this sample, a low number of participants with hip fracture received a clinical diagnosis of depression. Likely, due to these low
rates, we did not find that our candidate polymorphisms were related to a clinical diagnosis.
However, depressive symptoms, whether or not they meet criteria for a clinical diagnosis of depression, are still dangerous for patient’s health and are a barrier to successful recovery.
This was a study specifically designed to test for plasticity-related genetic effects on depressive symptoms after a disabling medical stressor. Depression is a heterogeneous disease, but in
this project we utilized hip fracture as a sort of natural experiment to test candidate genetic factors explicitly. This study included immediate recruitment of participants after hip fracture
and careful characterization of depressive symptoms.
Limitations included a small number of BDNF Met/Met carriers. The interaction finding is
preliminary and requires replication. A replication study could be accomplished in several
ways including studying BDNF levels, downstream functioning, or a sample with a higher
number of BDNF Met/Met carriers. Prior studies suggest the Met allele is more common in certain Asian populations [78] which may be a more ideal population to further examine Met/
Met effects.
In conclusion, our data indicates plasticity-related polymorphisms are associated with
higher depressive symptoms after a medical stressor in late-life and, subsequently, can negatively affect recovery. This knowledge is crucial for our aging population’s need to maintain independence. In addition, our data suggests a neurotrophin-serotonin link. As Kendler [79]
argues, it is unlikely we will uncover an exclusive genetic pattern revealing a heterogeneous illness such as depression; but it is possible to identify subsets of genetic interactions that delineate particular molecular pathways susceptible under certain genetic and environmental
conditions. The interaction identified here highlights the need to further study and understand
the neurobiological outcomes resulting from neurotrophin and neurotransmitter genetic interactions in stress-associated depression.
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